Amneal Pharmaceuticals, Inc. AMRX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Amneal Pharmaceuticals, Inc. (the "Company", "we," "us," or "our") is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States ("U.S."), India, and Ireland. Refer to the section "Segments of the Business" below for an overview of our segments.

Last close 20.38 2026-10-23
Market cap $6.51B 2026-06-30 share count
52-week range 9.99 - 21.18

Valuation FY2025 figures against the last close

P/S2.2x
P/E92.6x
P/FCF24.1x
EV/EBITDA19.5x
Dividend yield—
Diluted EPS0.22

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.02B$2.79B$2.39B$2.21B$2.09B$1.99B$1.63B$1.66B$1.03B$1.02B
Cost of revenue $1.91B$1.77B$1.57B$1.43B$1.32B$1.33B$1.15B$938.8M$507.5M$420.8M
Gross profit $1.11B$1.02B$820.6M$784.7M$769.0M$628.4M$353.0M$716.4M$526.2M$597.5M
R&D $186.2M$190.7M$163.9M$195.7M$201.8M$179.9M$188.0M$194.2M$171.4M$179.0M
SG&A $526.8M$476.4M$429.7M$399.7M$365.5M$326.7M$289.6M$227.8M$109.0M$118.8M
Operating income $394.1M$249.3M$204.4M-$94.9M$152.7M$91.2M-$248.7M-$19.7M$245.1M$284.9M
Pre-tax income $139.2M-$55.0M-$40.3M-$248.1M$31.4M-$35.8M-$220.2M-$202.7M$171.3M$214.8M
Income tax $11.3M$18.9M$8.5M$6.7M$11.2M$104.4M$383.3M$1.4M$2.0M$5.4M
Net income $72.1M-$116.9M-$84.0M-$254.8M$13.2M$67.8M-$603.6M-$19.7M$0$0
EPS, basic 0.23-0.38-0.48-0.860.070.62-2.74-0.16——
EPS, diluted 0.22-0.38-0.48-0.860.070.61-2.74-0.16——
Shares, diluted (wtd. avg.) 324.8M309.0M176.1M150.9M151.8M148.9M132.1M127.3M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $282.0M$110.6M$91.5M$35.2M$256.7M$347.1M$152.8M$218.8M$77.9M$37.5M
Receivables ———$741.8M$662.6M$638.9M$604.4M$481.5M$351.4M—
Inventory $606.3M$612.5M$581.4M$530.7M$489.4M$490.6M$381.1M$457.2M$284.0M—
Total current assets $1.91B$1.59B$1.38B$1.41B$1.52B$1.55B$1.21B$1.29B$771.9M—
Property, plant and equipment $442.9M$424.9M$447.6M$469.8M$514.2M$477.8M$478.0M$544.1M$486.8M—
Goodwill $595.5M$597.4M$598.6M$598.9M$593.0M$522.8M$419.5M$426.2M$26.4M$28.4M
Other intangibles $563.5M$732.4M$890.4M$1.10B$1.17B$1.30B$1.38B$1.65B$44.6M—
Total assets $3.68B$3.50B$3.47B$3.80B$3.94B$4.01B$3.67B$4.35B$1.34B—
Accounts payable ———$166.0M$131.1M$153.1M$103.0M$114.8M$70.0M—
Short-term debt $6.8M$224.2M$34.1M$30.0M$30.6M$44.2M$21.5M$21.4M$89.2M—
Total current liabilities $881.6M$1.13B$846.6M$752.8M$677.2M$676.9M$550.4M$553.9M$296.9M—
Long-term debt $2.57B$2.16B$2.39B$2.59B$2.68B$2.74B$2.61B$2.63B$1.36B—
Total liabilities ————————$0—
Retained earnings -$535.0M-$607.1M-$490.2M-$406.2M-$276.2M-$286.8M-$377.9M-$20.9M-$382.8M—
Total equity -$70.8M-$109.3M$20.0M$184.0M$367.0M$344.9M$346.8M$896.4M$0—

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $340.0M$295.1M$345.6M$65.1M$241.8M$379.0M$1.7M$250.2M$234.2M$115.1M
Depreciation and amortisation $57.3M$62.6M$66.2M$68.1M$60.7M$60.4M$63.3M$64.4M$42.0M$29.3M
Stock-based compensation $32.0M$27.8M$26.8M$31.8M$28.4M$20.8M$21.7M$167.6M$0$0
Capital expenditure $70.1M$51.9M$43.2M$46.4M$47.7M$56.4M$47.2M$83.1M$94.8M$122.8M
Investing cash flow -$112.3M-$63.0M-$69.2M-$174.3M-$194.2M-$317.5M-$19.6M-$396.4M-$98.6M-$124.6M
Financing cash flow -$31.5M-$211.8M-$212.6M-$106.6M-$138.1M$131.8M-$45.8M$287.7M-$95.0M-$19.5M
Dividends paid —————$0$0$183.0M$375.3M$200.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001723128-26-000011.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B 4B Revenue, FY2016: 1B Gross profit, FY2016: 597.5M Net income, FY2016: 0 Revenue, FY2017: 1B Gross profit, FY2017: 526.2M Net income, FY2017: 0 Revenue, FY2018: 1.7B Gross profit, FY2018: 716.4M Net income, FY2018: -19.7M Revenue, FY2019: 1.6B Gross profit, FY2019: 353M Net income, FY2019: -603.6M Revenue, FY2020: 2B Gross profit, FY2020: 628.4M Net income, FY2020: 67.8M Revenue, FY2021: 2.1B Gross profit, FY2021: 769M Net income, FY2021: 13.2M Revenue, FY2022: 2.2B Gross profit, FY2022: 784.7M Net income, FY2022: -254.8M Revenue, FY2023: 2.4B Gross profit, FY2023: 820.6M Net income, FY2023: -84M Revenue, FY2024: 2.8B Gross profit, FY2024: 1B Net income, FY2024: -116.9M Revenue, FY2025: 3B Gross profit, FY2025: 1.1B Net income, FY2025: 72.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.02B $1.03B $1.66B $1.63B $1.99B $2.09B $2.21B $2.39B $2.79B $3.02B
Gross profit $597.5M $526.2M $716.4M $353.0M $628.4M $769.0M $784.7M $820.6M $1.02B $1.11B
Net income $0 $0 -$19.7M -$603.6M $67.8M $13.2M -$254.8M -$84.0M -$116.9M $72.1M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Shareholder vote Item 5.07
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%